NASDAQ:IPSC - Century Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $36.25
  • Forecasted Upside: 46.41 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$24.76
▼ -4.49 (-15.35%)

This chart shows the closing price for IPSC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Century Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IPSC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IPSC

Analyst Price Target is $36.25
▲ +46.41% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Century Therapeutics in the last 3 months. The average price target is $36.25, with a high forecast of $40.00 and a low forecast of $33.00. The average price target represents a 46.41% upside from the last price of $24.76.

This chart shows the closing price for IPSC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in Century Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/21/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/20/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/15/2021SVB LeerinkReiterated RatingBuyHigh
7/13/2021SVB LeerinkInitiated CoverageOutperform$33.00High
7/13/2021JPMorgan Chase & Co.Initiated CoverageOverweight$40.00High
7/13/2021Bank of AmericaInitiated CoverageBuy$34.00High
7/13/2021Piper SandlerInitiated CoverageOverweight$38.00High
(Data available from 9/20/2016 forward)

News Sentiment Rating

0.40 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/24/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/22/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/22/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/21/2021
  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/20/2021

Current Sentiment

  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.
Century Therapeutics logo
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT or CAR-iNK candidate targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia. The company was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
Read More

Today's Range

Now: $24.76
Low: $24.51
High: $30.32

50 Day Range

MA: $27.74
Low: $23.32
High: $31.93

52 Week Range

Now: $24.76
Low: $18.92
High: $32.90

Volume

1,672,200 shs

Average Volume

245,354 shs

Market Capitalization

$1.35 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Century Therapeutics?

The following Wall Street sell-side analysts have issued stock ratings on Century Therapeutics in the last year: Bank of America Co., JPMorgan Chase & Co., Piper Sandler, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for IPSC.

What is the current price target for Century Therapeutics?

4 Wall Street analysts have set twelve-month price targets for Century Therapeutics in the last year. Their average twelve-month price target is $36.25, suggesting a possible upside of 46.4%. JPMorgan Chase & Co. has the highest price target set, predicting IPSC will reach $40.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $33.00 for Century Therapeutics in the next year.
View the latest price targets for IPSC.

What is the current consensus analyst rating for Century Therapeutics?

Century Therapeutics currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IPSC will outperform the market and that investors should add to their positions of Century Therapeutics.
View the latest ratings for IPSC.

What other companies compete with Century Therapeutics?

How do I contact Century Therapeutics' investor relations team?

The company's listed phone number is 215-981-4000 and its investor relations email address is [email protected] The official website for Century Therapeutics is www.centurytx.com.